A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.
about
One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonatesOne dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonatesEfficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis.Pharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature ReviewAudiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-upCharacteristics and dynamics of bacterial populations during postantibiotic effect determined by flow cytometry.Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients.Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Aminoglycoside dosing in diabetes.Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administrationProspective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicityNonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection modelDetermination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infectionIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Gentamicin dosing in critically ill patients.Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside.Ototoxicity induced by gentamicin and furosemide.Once-daily aminoglycosides in patients with neutropenic fever.Clinical issues surrounding once-daily aminoglycoside dosing in children.Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patientsAminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.Meta-analysis and investigation of anti-infective therapies.High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital PharmacistsCurrent use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.Symptom reporting compared with audiometry for the detection of cochleotoxicity in patients on long-term aminoglycoside therapy.Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.Aminoglycoside-induced nephrotoxicity.Nanocarrier-based interventions for the management of MDR/XDR-TB.Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review.Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditisPharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients.The effectiveness and safety of two prophylactic antibiotic regimes in hip-fracture surgery.Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?State of the evidence: current status and prospects of meta-analysis in infectious diseases.Sensorineural deafness following routine transurethral resection of the prostate.
P2860
Q24235032-0CCFBFDC-1A3E-4E46-90D9-8DD7588264E1Q24244642-F157E98D-93C1-4F60-818A-D4E22AE17794Q28345165-3942CE6B-9E70-493C-8592-F5624F2A61AEQ29248398-19AE430A-0BED-46A7-9426-9ECFA07A6D34Q30838132-5CF1C1E6-9E86-4CE1-8147-AC9A25B617B2Q33695042-B08D4FB9-FD02-4DFE-9FD4-F62203E791C9Q33695881-85AB3A10-07C9-48AA-9618-C21CF47E6666Q33753500-CDC9DD85-365C-4102-B03E-5AC738157F4CQ33940442-271ED8BF-EBC5-4ABE-9E2C-B077E9137CC2Q33976169-D997DCFB-491D-4C91-812C-DC138C0F37DFQ33977062-A2F36B5C-E965-4C37-8E8F-423992917A96Q34106577-469AE624-B25C-4E95-9359-2D5603D62DDFQ34106959-DA127C3D-CD4D-4EAF-B16A-385BE3D06072Q34141627-ED83A5EE-14BD-43DD-8772-A9419039AB7BQ34274190-4B5B1063-C1A8-4900-9DB5-8B147BAB35B7Q34291143-09604A39-1468-49B3-BFF7-89CE13125D5EQ34443415-43CD5E8F-1D96-455D-90C6-E5FFB5AD51A0Q34521641-9B5C7351-8639-48BB-B675-AF6886906923Q34985783-D7A1DE6E-414F-4E01-80FD-521405A84388Q35043373-D0FF3450-FA8A-41D4-89C6-DBA524BC62E3Q35221045-54C81DBF-1AA5-4D35-A258-7841FAF6FBC0Q35297198-E0955440-7CBE-40AB-86BB-ED593B00A74BQ35745888-66014E75-F9B9-4C1C-B9A6-1726F6F5EAB7Q35806154-E58B414C-AD56-42B8-B0F5-B03A3F95F679Q36053463-CDC39213-C0DF-43CF-B74B-0FE552171D54Q36179740-E8E23012-4F8D-45DE-8F5E-C99BC5913C06Q37376795-05D5240A-C235-491C-A498-1B8FF6E6B9F7Q37839231-3D05C300-D07C-4F20-A550-18A0797AB3CFQ37869273-F72F5EA0-EA56-446F-B389-CDE852BB4758Q38070006-A89B0F2E-D7BD-4D67-8430-BFB5691C29F6Q38090988-EBB31101-6739-4011-B5F6-1862D2F4A4CCQ38246945-F935D52C-493E-4AD5-BEF0-8F07F25F598EQ38375982-CB942619-3703-4C7E-8244-78B7F8D2C8FFQ38919674-3F3B487E-70ED-4A2A-BDCF-68549F44F271Q39477095-88E7F30D-A116-4048-B35A-F47895B336CCQ40643970-57E975C4-CC52-40BB-8B65-9606E69ED2FDQ40668918-2F020A12-22BA-447D-A836-682EDCB168D0Q41676743-6A4F18E9-1248-46BD-9C84-22CA56106E7BQ42612025-47A1B7AE-59A2-4750-AF7F-AF5C0A9832B6Q43162717-728EA8BB-EB78-4EEB-8C72-990EBB62482B
P2860
A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
A meta-analysis of studies on ...... nce daily or as divided doses.
@ast
A meta-analysis of studies on ...... nce daily or as divided doses.
@en
A meta-analysis of studies on ...... nce daily or as divided doses.
@nl
type
label
A meta-analysis of studies on ...... nce daily or as divided doses.
@ast
A meta-analysis of studies on ...... nce daily or as divided doses.
@en
A meta-analysis of studies on ...... nce daily or as divided doses.
@nl
prefLabel
A meta-analysis of studies on ...... nce daily or as divided doses.
@ast
A meta-analysis of studies on ...... nce daily or as divided doses.
@en
A meta-analysis of studies on ...... nce daily or as divided doses.
@nl
P2093
P356
P1476
A meta-analysis of studies on ...... nce daily or as divided doses.
@en
P2093
Grayson ML
Munckhof WJ
Turnidge JD
P304
P356
10.1093/JAC/37.4.645
P407
P577
1996-04-01T00:00:00Z